Nature Biotechnology, Published online: 19 November 2025; doi:10.1038/s41587-025-02923-2
Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Firefly Bio seeks to improve on antibody–drug conjugates and proteolysis-targeting chimeras by combining them as degrader–antibody conjugates.
Nature Biotechnology, Published online: 19 November 2025; doi:10.1038/s41587-025-02923-2Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Firefly Bio seeks to improve on antibody–drug conjugates and proteolysis-targeting chimeras by combining them as degrader–antibody conjugates. Read More
